Rybrevant Phase III MARIPOSA-2 study meets dual primary endpoint

US healthcare giant Johnson & Johnson (NYSE: JNJ) subsidiary has released positive top-line results from the three-arm Phase III MARIPOSA-2 study evaluating Rybrevant (amivantamab-vmjw) in lung cancer patients.

Rybrevant, is a bispecific antibody targeting epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition (MET), given with and without lazertinib, an oral, third-generation EGFR tyrosine kinase inhibitor (TKI), combined with chemotherapy (carboplatin and pemetrexed) versus chemotherapy alone.

MARIPOSA-2 enrolled patients with locally advanced or metastatic EGFR exon 19 deletions (ex19del) or L858R substitution non-small cell lung cancer (NSCLC) after disease progression on or after osimertinib. The study met its dual primary endpoint, demonstrating a statistically-significant and clinically meaningful improvement in PFS versus chemotherapy alone in both experimental treatment arms.